Cargando…

Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Detalles Bibliográficos
Autores principales:	Kotsianidis, Ioannis, Papageorgiou, Sotirios G., Pappa, Vassiliki, Galanopoulos, Athanasios G., Viniou, Nora-Athina, Vassilakopoulos, Theodoros P., Papoutselis, Menelaos, Vrachiolias, George, Papadopoulos, Vasileios, Diamantopoulos, Panagiotis T., Tsokanas, Dimitris, Kourakli, Alexandra, Symeonidis, Argiris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2019
Materias:	Scientific Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613620/ https://www.ncbi.nlm.nih.gov/pubmed/31308921 http://dx.doi.org/10.4084/MJHID.2019.045

Ejemplares similares

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
por: Diamantopoulos, Panagiotis, et al.
Publicado: (2019)

Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study
por: Liapis, Konstantinos, et al.
Publicado: (2020)

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
por: Papageorgiou, Sotirios G., et al.
Publicado: (2020)

Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes
por: Mitroulis, Ioannis, et al.
Publicado: (2023)

Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes
por: Diamantopoulos, P, et al.
Publicado: (2017)

CD34 and p53 Immunohistochemical Stains Differentiate Hypocellular Myelodysplastic Syndrome (hMDS) from Aplastic Anemia and a CD34 Immunohistochemical Stain Provides Useful Survival Information for hMDS
por: Cha, Choong-Hwan, et al.
Publicado: (2014)

P706: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISKMYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINEDEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME
por: Dimitriou, Despoina, et al.
Publicado: (2023)

Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression
por: Kazachenka, Anastasiya, et al.
Publicado: (2019)

Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations
por: Diamantopoulos, Panagiotis T, et al.
Publicado: (2012)

Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management
por: Thomopoulos, Thomas P., et al.
Publicado: (2022)

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients’ outcome?
por: Bouchla, Anthi, et al.
Publicado: (2023)

Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine
por: Miltiades, P, et al.
Publicado: (2014)

Blood and platelet transfusion from a donor with presymptomatic Covid-19
por: Liapis, Konstantinos, et al.
Publicado: (2020)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients
por: Spetsieris, Nikolaos, et al.
Publicado: (2018)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

P1606: PRIMARY AND SECONDARY IMMUNE THROMBOCYTOPENIA (ITP) IN ADULTS: REAL WORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY
por: Stavroulaki, Emily, et al.
Publicado: (2023)

P1646: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN PATIENTS OLDER THAN 75 YEARS: REAL WORLD DATA FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY
por: Pontikoglou, C., et al.
Publicado: (2022)

The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
por: Kontandreopoulou, Christina-Nefeli, et al.
Publicado: (2022)

PB1992: PROTEOMIC ANALYSIS REVEALS AUTOPHAGY INHIBITION IN MYELODYSPLASTIC SYNDROMES
por: Tsekoura, Georgia, et al.
Publicado: (2023)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine
por: HISASUE, Masaharu, et al.
Publicado: (2021)

Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
por: Dubois, Alix, et al.
Publicado: (2020)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

The incidence of myelodysplastic syndromes in Western Greece is increasing
por: Avgerinou, Christina, et al.
Publicado: (2013)

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome
por: Kontandreopoulou, Christina-Nefeli, et al.
Publicado: (2021)

Deregulation of Autophagy and Apoptosis in Patients with Myelodysplastic Syndromes: Implications for Disease Development and Progression
por: Tsekoura, Georgia, et al.
Publicado: (2023)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

Contingent Synergistic Interactions between Non-Coding RNAs and DNA-Modifying Enzymes in Myelodysplastic Syndromes
por: Symeonidis, Argiris, et al.
Publicado: (2022)

P705: AZACYTIDINE THERAPY REVERTS MDS-ASSOCIATED CHANGES IN MSC-DERIVED EXTRACELLULAR MATRIX
por: Bains, Amanpreet, et al.
Publicado: (2023)

Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
por: Xie, Xiaoqing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_crlc4qsiqjau595cihrd7unrbo